Treatment of Guillain-Barré Syndrome AMSAN Variant

First-Line Treatment Options

The American Academy of Neurology recommends treating AMSAN with intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 consecutive days, which is equally effective as plasma exchange but preferred due to easier administration and wider availability 1, 2
IVIg is generally preferred over plasma exchange due to its higher completion rates, easier administration, and wider availability 1, 2
Plasma exchange (200-250 ml/kg over 5 sessions) remains an equally effective alternative, particularly in resource-limited settings where cost is a major factor 2, 3

Initiate treatment immediately in patients unable to walk unaided with moderate to severe weakness, especially with rapid progression 1, 2
Treatment should begin within 2 weeks of symptom onset for maximum effectiveness 1, 2
AMSAN patients often present later and more severely than AIDP patients, making early recognition crucial 3

Admit all patients to a monitored unit with rapid ICU transfer capability, as approximately 25% of GBS patients develop respiratory failure 2
Use the "20/30/40 rule" to assess respiratory failure risk: patient at risk if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1, 2
Calculate EGRIS (Erasmus GBS Respiratory Insufficiency Score) to predict probability of requiring mechanical ventilation within 1 week 1, 2

Never use corticosteroids alone, as they are ineffective and may worsen outcomes 1, 2
Avoid medications that worsen neuromuscular function: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 1, 2

Approximately 40% of patients do not improve in the first 4 weeks following treatment, which does not necessarily indicate treatment failure 1, 2
Treatment-related fluctuations (TRFs) occur in 6-10% of patients within 2 months of initial improvement, and repeating the full course of IVIg or plasma exchange is appropriate 1, 2

Manage neuropathic pain with gabapentin, pregabalin, or duloxetine, and avoid opioids 1, 2
Provide DVT prophylaxis and pressure ulcer prevention 1
Address constipation/ileus, which is common in GBS patients 1
Evaluate for dysphagia and provide nutritional support if necessary 1

About 80% of GBS patients overall regain walking ability at 6 months 1, 2
Mortality remains 3-10%, primarily from cardiovascular and respiratory complications 1, 2

Small volume plasma exchange (SVPE) is a novel, low-cost alternative that has shown safety and feasibility, though large-scale efficacy studies are still needed 3
Standard IVIg and plasma exchange remain unaffordable for most patients in these settings 3

The American Academy of Neurology considers monitoring of swallowing and coughing difficulties crucial to prevent aspiration in AMSAN patients 4
Assessing bowel and bladder function for autonomic involvement is essential in AMSAN patients, according to the Nature Reviews Neurology 4
Serial neurologic examinations using Medical Research Council grading scale and GBS disability scale are recommended for AMSAN patients 4
Pressure ulcer prevention with frequent repositioning is a critical supportive measure in immobilized AMSAN patients 4
Treatment of constipation/ileus is common in AMSAN patients and should be managed accordingly 5

Macrolides should be avoided in AMSAN patients as they can worsen neuromuscular function, according to the Journal of Clinical Oncology 5

Up to two-thirds of deaths in AMSAN patients occur during the recovery phase, mostly from cardiovascular and respiratory dysfunction, highlighting the need for continued vigilance, as noted in Nature Reviews Neurology 4